| 15.76 -2.24 (-12.44%) | 03-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 22.04 | 1-year : | 25.74 |
| Resists | First : | 18.87 | Second : | 22.04 |
| Pivot price | 16.19  |
|||
| Supports | First : | 14.69 | Second : | 12.1 |
| MAs | MA(5) : | 17.59 |
MA(20) : | 15.48 |
| MA(100) : | 14.78 |
MA(250) : | 11.39 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 76.8 |
D(3) : | 86.3 |
| RSI | RSI(14): 48.7 |
|||
| 52-week | High : | 19.11 | Low : | 3.91 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ EYPT ] has closed above bottom band by 44.0%. Bollinger Bands are 83.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 18 - 18.15 | 18.15 - 18.24 |
| Low: | 15.25 - 15.39 | 15.39 - 15.49 |
| Close: | 15.57 - 15.79 | 15.79 - 15.94 |
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Thu, 05 Mar 2026
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Thu, 05 Mar 2026
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target Raised to $30.00 - MarketBeat
Thu, 05 Mar 2026
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2025 Earnings Call Transcript - Insider Monkey
Wed, 04 Mar 2026
Chardan Capital Issues Positive Forecast for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price - MarketBeat
Wed, 04 Mar 2026
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 4.7% - Should You Sell? - MarketBeat
Wed, 04 Mar 2026
EYEPOINT PHARMACEUTICALS ($EYPT) Releases Q4 2025 Earnings - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 83 (M) |
| Held by Insiders | 6.119e+007 (%) |
| Held by Institutions | 2.7 (%) |
| Shares Short | 8,630 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.1625e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -6 % |
| Return on Assets (ttm) | 420.8 % |
| Return on Equity (ttm) | -49.4 % |
| Qtrly Rev. Growth | 4.234e+007 % |
| Gross Profit (p.s.) | -50.73 |
| Sales Per Share | -54.88 |
| EBITDA (p.s.) | -9.01788e+007 |
| Qtrly Earnings Growth | -3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -211 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.29 |
| Price to Cash Flow | 9.79 |
| Dividend | 0 |
| Forward Dividend | 8.64e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|